According to the market analysis report titled ‘Global Non-Invasive Prenatal Testing Market: Demand, Insights, Analysis, Opportunities, Growth Potential and Forecast 2018 – 2025’, available with MarketStudyReport, global non-invasive prenatal testing market is expected to exceed a valuation of USD 2.5 Bn by 2025.
 

Industry doyens are of the opinion that global non-invasive prenatal testing market is driven by the high birth-rate of infants born with down syndrome, and rising preference towards the testing owing to negligible risk of miscarriage owing to a NIPT test.
 

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/1162034/
 

Rising number of women wanting to embrace motherhood at an advanced age (35 or older) and increasing reimbursement for NIPT procedures are also adding considerable momentum to industry development.
 

Apart from growth drivers and opportunities, the research literature also sheds light on current and upcoming challenges in the business sphere, while also divulging solutions. It also considers the market augmentation history, as well as current trends, to produce reliable estimates regarding market size and demand, volume of NIPT tests conducted, revenue shares, and future growth potential during the timeframe of 2018-2025.
 

Based on test type, the worldwide non-invasive prenatal testing market is fragmented into Panorama, NIFTY, MaterniT21, Verifi, Harmony, Prena, IONA, Veracity, Bambni, and other.


The business report also provides a comprehensive analysis on major partnership and collaboration deals, mergers and acquisitions, capital investments, distribution channels, and licensing agreements, thereby enabling the stakeholders to make informed decisions and reap maximum profits.
 

From a regional frame of reference, the major revenue generating avenues for the industry are United States, Australia, China, India, Japan, Brazil, Russia, New Zealand, Germany, United Kingdom, Italy, Sweden, France, Spain, Switzerland, Netherlands, Demark, Turkey, Poland, Moldova, and Armenia. Among these, the markets in USA and China are the most promising over the forecast period, with the latter expected to amass USD 400 Mn by 2025 owing to the prevalence of two child policy in the country.

Speaking of the competitive landscape, reputed companies like Ariosa Diagnostics (Roche), Natera Inc., Sequenom, Illumina Inc., BGI Group, Quest Diagnostics, Berry Genomics, Premaitha Health (Yourgene Health PLC), and LifeCodexx AG are thoroughly analyzed within the report.

The aforementioned players are assessed with respect to company overview, recent developments, and NIPT test portfolios to gauge their impact on the overall functioning of the non-invasive prenatal testing market during the aforementioned timeframe.